Literature DB >> 11596042

Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma.

B L Brücher1, H J Stein, M Werner, J R Siewert.   

Abstract

BACKGROUND: Little data exist about the prognostic role of a lymphatic vessel invasion (LVI) in patients with esophageal carcinoma. The objective of this study was to clarify the presence and prognostic impact of LVI in a large group of patients resected for esophageal squamous cell carcinoma (SCC) at one surgical center.
METHODS: Three hundred sixty-six patients, who had a primary resection for SCC, were analyzed by univariate and multivariate analysis. Follow-up was complete for 93.7% patients with a median follow-up of 8.3 years.
RESULTS: The total rate of LVI was 39.1% (n = 143). Univariate analysis revealed a significant relation between LVI and different T classifications (P = 0.001), N classifications (P < 0.0001), M classifications (P < 0.0001), International Union Against Cancer (UICC) stages (P < 0.0001), and residual tumor (P < 0.0001). Multivariate analysis of the patients with R0-resected tumors proved LVI as an independent prognostic factor. The 2-, 5- and 10-year survival rates in patients with LVI were 28.5%, 11.1%, and 9.2% compared with 63.4%, 46.6%, and 27%, respectively, without LVI (P < 0.0001). Patients with LVI had a median survival time of 11.4 months compared with 28.6 months without LVI (P < 0.0001). Patients with R0-resected tumors without LVI had a median survival time of 54.1 months compared with 12.1 months in patients with LVI (P < 0.0001) and compared with 11.3 months in patients with R1-resected tumors P < 0.0001).
CONCLUSIONS: These data clearly show that LVI is an independent prognostic factor in patients with SCC and confirm the importance of a systematic pathohistologic workup. The prognosis of patients with R0-resected tumors with LVI is equal to patients with an incomplete tumor resection. This supports the inclusion of LVI in the UICC classification system for esophageal carcinoma. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11596042     DOI: 10.1002/1097-0142(20011015)92:8<2228::aid-cncr1567>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Impact of lymphatic vessel invasion on survival in gastric cancer.

Authors:  Fusun Ozmen; M Mahir Ozmen; Emin Kansu
Journal:  J Gastrointest Surg       Date:  2012-03-13       Impact factor: 3.452

2.  Predictions of Pathological Features and Recurrence Based on FDG-PET Findings of Esophageal Squamous Cell Carcinoma after Trimodal Therapy.

Authors:  Yoichi Hamai; Manabu Emi; Yuta Ibuki; Yuji Murakami; Ikuno Nishibuchi; Yasushi Nagata; Takaoki Furukawa; Tomoaki Kurokawa; Manato Ohsawa; Toru Yoshikawa; Morihito Okada
Journal:  Ann Surg Oncol       Date:  2020-05-13       Impact factor: 5.344

3.  Impact of lymphatic and/or blood vessel invasion in stage II gastric cancer.

Authors:  Chun-Yan Du; Jing-Gui Chen; Ye Zhou; Guang-Fa Zhao; Hong Fu; Xue-Ke Zhou; Ying-Qiang Shi
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

4.  Impact of lymphatic vessel invasion on survival in curative resected gastric cancer.

Authors:  Enyi Liu; Meizuo Zhong; Fang Xu; Wei Liu; Jin Huang; Shan Zeng; Jingchen Lu; Bin Li; Jianhuang Li; Hairong Jiang
Journal:  J Gastrointest Surg       Date:  2011-06-30       Impact factor: 3.452

5.  Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection.

Authors:  Hubert J Stein; Marcus Feith; Bjorn L D M Bruecher; Jorg Naehrig; Mario Sarbia; J Rudiger Siewert
Journal:  Ann Surg       Date:  2005-10       Impact factor: 12.969

6.  An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus.

Authors:  Bas P L Wijnhoven; Khe T C Tran; Adrian Esterman; David I Watson; Hugo W Tilanus
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

7.  Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy.

Authors:  Björn L D M Brücher; Gisela Keller; Martin Werner; Ulrike Müller; Silke Lassmann; Antonello Domenico Cabras; Falko Fend; Raymonde Busch; Hubert Stein; Hans-Dieter Allescher; Michael Molls; J Rüdiger Siewert; Heinz Höfler; Katja Specht
Journal:  Int J Colorectal Dis       Date:  2008-08-13       Impact factor: 2.571

8.  Lymph node metastasis density and growth pattern as independent prognostic factors in advanced esophageal squamous cell carcinoma.

Authors:  Akira Ooki; Keishi Yamashita; Nobuyuki Kobayashi; Natsuya Katada; Shinichi Sakuramoto; Shiroh Kikuchi; Masahiko Watanabe
Journal:  World J Surg       Date:  2007-08-24       Impact factor: 3.352

Review 9.  [Esophageal squamous cell carcinoma: pre-operative combined radiochemotherapy from a surgical oncological viewpoint].

Authors:  B L D M Brücher
Journal:  Chirurg       Date:  2009-11       Impact factor: 0.955

Review 10.  [Curative vs palliative strategies in locoregional recurrence of gastrointestinal malignancies].

Authors:  J R Siewert; F Lordick; K Ott; B L D M Brücher; R Rosenberg
Journal:  Chirurg       Date:  2006-03       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.